Overview

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Status:
RECRUITING

Trial end date:
2026-12-10

Target enrollment:

Participant gender:

Summary

Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD

Phase:

PHASE2

Details

Lead Sponsor:

St. Petersburg State Pavlov Medical University

Treatments:

Abatacept
ruxolitinib